Just – Evotec Biologics expands tech partnership for biosimilars...
Evotec SE today announced that its biologics segment, Just – Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz. Just – Evotec Biologics will receive appropriate remuneration...
View ArticleEvotec and Pfizer collaborate to advance drug discovery in France
Evotec SE today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on...
View Article65LAB and Duke-NUS award US$1.85 million to combat chronic inflammation
Associate Professor Lena Ho from Duke-NUS Medical School has been awarded US$1.85 million (approx. S$2.51 million) to further her team’s research in developing microproteins into therapeutic targets to...
View ArticleAd hoc: Evotec SE provides guidance update
Evotec SE announces that it has refined its guidance for the fiscal year 2024.
View ArticleEvotec provides guidance update
Evotec SE today announced that it has refined its guidance for the fiscal year 2024.
View ArticleEvotec SE reports first half-year 2024 results on 14 August 2024
Evotec SE will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.
View ArticleEvotec announces progress in strategic neuroscience partnership with...
Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$...
View ArticleEvotec announces progress in protein degradation partnership with BMS
Evotec SE today announced further strong progress of the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and...
View ArticleEvotec SE reports H1 2024 results
Evotec SE today announced its financial results and corporate updates for the first half-year of 2024.
View ArticleEvotec announces change in Management Board
Evotec SE today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024....
View ArticleEvotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
Evotec SE and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery.
View ArticleJust – Evotec Biologics opens biologics facility - J.POD® Toulouse (EU)
Just – Evotec Biologics, the biologics segment of Evotec SE, today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec’s Campus Curie in...
View ArticleEvotec and Novo Nordisk enter technology development partnership
Evotec SE announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.
View ArticleEvotec and Bristol Myers Squibb expand proteomics partnership
Evotec SE announced progress within the company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
View ArticleEvotec SE reports 9-month 2024 results on 6 November 2024
Evotec SE will announce its financial results for the first nine months of 2024 on Wednesday, 6 November 2024.
View ArticleEvotec Announces Sale of API Manufacturing Facility to Monacum Partners
Evotec SE has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm.
View ArticleEvotec SE reports 9M 2024 results
Evotec SE today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations.
View ArticleEVOTEC RECEIVES SBTi APPROVAL FOR ITS NET-ZERO SCIENCE-BASED TARGETS
Evotec SE today announced that the Company’s greenhouse gas (“GHG”) near-term and long-term emissions reduction targets have been validated and approved by the Science Based Targets initiative...
View ArticleAd hoc: Comment on media report
With respect to a media report, Evotec SE declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc....
View ArticleAd hoc: Comment on withdrawn non-binding offer
Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for...
View Article